204 related articles for article (PubMed ID: 25207814)
1. MID1 catalyzes the ubiquitination of protein phosphatase 2A and mutations within its Bbox1 domain disrupt polyubiquitination of alpha4 but not of PP2Ac.
Du H; Wu K; Didoronkute A; Levy MV; Todi N; Shchelokova A; Massiah MA
PLoS One; 2014; 9(9):e107428. PubMed ID: 25207814
[TBL] [Abstract][Full Text] [Related]
2. Structural and functional observations of the P151L MID1 mutation reveal alpha4 plays a significant role in X-linked Opitz Syndrome.
Wright KM; Du H; Massiah MA
FEBS J; 2017 Jul; 284(14):2183-2193. PubMed ID: 28548391
[TBL] [Abstract][Full Text] [Related]
3. XLOS-observed mutations of MID1 Bbox1 domain cause domain unfolding.
Wright KM; Wu K; Babatunde O; Du H; Massiah MA
PLoS One; 2014; 9(9):e107537. PubMed ID: 25216264
[TBL] [Abstract][Full Text] [Related]
4. The E3 ubiquitin ligase MID1/TRIM18 promotes atypical ubiquitination of the BRCA2-associated factor 35, BRAF35.
Zanchetta ME; Napolitano LMR; Maddalo D; Meroni G
Biochim Biophys Acta Mol Cell Res; 2017 Oct; 1864(10):1844-1854. PubMed ID: 28760657
[TBL] [Abstract][Full Text] [Related]
5. The MID1 E3 ligase catalyzes the polyubiquitination of Alpha4 (α4), a regulatory subunit of protein phosphatase 2A (PP2A): novel insights into MID1-mediated regulation of PP2A.
Du H; Huang Y; Zaghlula M; Walters E; Cox TC; Massiah MA
J Biol Chem; 2013 Jul; 288(29):21341-21350. PubMed ID: 23740247
[TBL] [Abstract][Full Text] [Related]
6. Detection and characterization of the in vitro e3 ligase activity of the human MID1 protein.
Han X; Du H; Massiah MA
J Mol Biol; 2011 Apr; 407(4):505-20. PubMed ID: 21296087
[TBL] [Abstract][Full Text] [Related]
7. Alpha4 is a ubiquitin-binding protein that regulates protein serine/threonine phosphatase 2A ubiquitination.
McConnell JL; Watkins GR; Soss SE; Franz HS; McCorvey LR; Spiller BW; Chazin WJ; Wadzinski BE
Biochemistry; 2010 Mar; 49(8):1713-8. PubMed ID: 20092282
[TBL] [Abstract][Full Text] [Related]
8. The E3 ubiquitin ligase- and protein phosphatase 2A (PP2A)-binding domains of the Alpha4 protein are both required for Alpha4 to inhibit PP2A degradation.
LeNoue-Newton M; Watkins GR; Zou P; Germane KL; McCorvey LR; Wadzinski BE; Spiller BW
J Biol Chem; 2011 May; 286(20):17665-71. PubMed ID: 21454489
[TBL] [Abstract][Full Text] [Related]
9. NMR studies of the C-terminus of alpha4 reveal possible mechanism of its interaction with MID1 and protein phosphatase 2A.
Du H; Massiah MA
PLoS One; 2011; 6(12):e28877. PubMed ID: 22194938
[TBL] [Abstract][Full Text] [Related]
10. Molecular dynamics simulation reveals insights into the mechanism of unfolding by the A130T/V mutations within the MID1 zinc-binding Bbox1 domain.
Zhao Y; Zeng C; Massiah MA
PLoS One; 2015; 10(4):e0124377. PubMed ID: 25874572
[TBL] [Abstract][Full Text] [Related]
11. Active transport of the ubiquitin ligase MID1 along the microtubules is regulated by protein phosphatase 2A.
Aranda-Orgillés B; Aigner J; Kunath M; Lurz R; Schneider R; Schweiger S
PLoS One; 2008; 3(10):e3507. PubMed ID: 18949047
[TBL] [Abstract][Full Text] [Related]
12. Protein phosphatase 2A (PP2A)-specific ubiquitin ligase MID1 is a sequence-dependent regulator of translation efficiency controlling 3-phosphoinositide-dependent protein kinase-1 (PDPK-1).
Aranda-Orgillés B; Rutschow D; Zeller R; Karagiannidis AI; Köhler A; Chen C; Wilson T; Krause S; Roepcke S; Lilley D; Schneider R; Schweiger S
J Biol Chem; 2011 Nov; 286(46):39945-57. PubMed ID: 21930711
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of midline defect-causing mutation P151L in MID1 revealed.
Nicholson LK
FEBS J; 2017 Jul; 284(14):2167-2169. PubMed ID: 28714291
[TBL] [Abstract][Full Text] [Related]
14. A structure-function study of MID1 mutations associated with a mild Opitz phenotype.
Mnayer L; Khuri S; Merheby HA; Meroni G; Elsas LJ
Mol Genet Metab; 2006 Mar; 87(3):198-203. PubMed ID: 16378742
[TBL] [Abstract][Full Text] [Related]
15. A MID1 mutation associated with reduced penetrance of X-linked Opitz G/BBB syndrome.
Ruiter M; Kamsteeg EJ; Meroni G; de Vries BBA
Clin Dysmorphol; 2010 Oct; 19(4):195-197. PubMed ID: 20671548
[TBL] [Abstract][Full Text] [Related]
16. Control of mTORC1 signaling by the Opitz syndrome protein MID1.
Liu E; Knutzen CA; Krauss S; Schweiger S; Chiang GG
Proc Natl Acad Sci U S A; 2011 May; 108(21):8680-5. PubMed ID: 21555591
[TBL] [Abstract][Full Text] [Related]
17. Complex rearrangement of the exon 6 genomic region among Opitz G/BBB Syndrome MID1 alterations.
Migliore C; Athanasakis E; Dahoun S; Wonkam A; Lees M; Calabrese O; Connell F; Lynch SA; Izzi C; Pompilii E; Thakur S; van Maarle M; Wilson LC; Meroni G
Eur J Med Genet; 2013 Aug; 56(8):404-10. PubMed ID: 23791568
[TBL] [Abstract][Full Text] [Related]
18. Embryonic expression of the human MID1 gene and its mutations in Opitz syndrome.
Pinson L; Augé J; Audollent S; Mattéi G; Etchevers H; Gigarel N; Razavi F; Lacombe D; Odent S; Le Merrer M; Amiel J; Munnich A; Meroni G; Lyonnet S; Vekemans M; Attié-Bitach T
J Med Genet; 2004 May; 41(5):381-6. PubMed ID: 15121778
[No Abstract] [Full Text] [Related]
19. Mig12, a novel Opitz syndrome gene product partner, is expressed in the embryonic ventral midline and co-operates with Mid1 to bundle and stabilize microtubules.
Berti C; Fontanella B; Ferrentino R; Meroni G
BMC Cell Biol; 2004 Feb; 5():9. PubMed ID: 15070402
[TBL] [Abstract][Full Text] [Related]
20. A novel mutation in MID1 in a patient with X-linked Opitz G/BBB syndrome.
Ji X; Xing Y; Xu Y; Liu Y; Chen Y; Tao J; Xiao B
Gene; 2014 Mar; 537(1):140-2. PubMed ID: 24374473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
